Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Other Non-Current Assets (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Other Non-Current Assets for 9 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets changed N/A to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $1.2 million for FY2025, N/A changed from the prior year.
  • Other Non-Current Assets for Q4 2025 was $1.2 million at Crescent Biopharma, up from $107000.0 in the prior quarter.
  • The five-year high for Other Non-Current Assets was $2.2 million in Q1 2022, with the low at $50000.0 in Q4 2022.
  • Average Other Non-Current Assets over 5 years is $655597.3, with a median of $122052.5 recorded in 2024.
  • The sharpest move saw Other Non-Current Assets soared 4145.81% in 2022, then tumbled 97.75% in 2023.
  • Over 5 years, Other Non-Current Assets stood at $1.6 million in 2021, then crashed by 96.8% to $50000.0 in 2022, then skyrocketed by 1107.47% to $603737.0 in 2023, then plummeted by 91.33% to $52320.0 in 2024, then soared by 2224.16% to $1.2 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $1.2 million, $107000.0, and $106000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.